SE9704549L - Läkemedelsdistributionssystem - Google Patents

Läkemedelsdistributionssystem

Info

Publication number
SE9704549L
SE9704549L SE9704549A SE9704549A SE9704549L SE 9704549 L SE9704549 L SE 9704549L SE 9704549 A SE9704549 A SE 9704549A SE 9704549 A SE9704549 A SE 9704549A SE 9704549 L SE9704549 L SE 9704549L
Authority
SE
Sweden
Prior art keywords
drug
delivery system
drug delivery
target
cells
Prior art date
Application number
SE9704549A
Other languages
English (en)
Other versions
SE513149C2 (sv
SE9704549D0 (sv
Inventor
Katarina Edwards
Joergen Carlsson
Stefan Sjoeberg
Original Assignee
Katarina Edwards
Joergen Carlsson
Stefan Sjoeberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katarina Edwards, Joergen Carlsson, Stefan Sjoeberg filed Critical Katarina Edwards
Priority to SE9704549A priority Critical patent/SE513149C2/sv
Publication of SE9704549D0 publication Critical patent/SE9704549D0/sv
Priority to CA002312767A priority patent/CA2312767C/en
Priority to PCT/SE1998/002231 priority patent/WO1999029302A1/en
Priority to US09/555,329 priority patent/US6562316B1/en
Priority to AU17938/99A priority patent/AU745059B2/en
Priority to AT98962780T priority patent/ATE247949T1/de
Priority to JP2000523974A priority patent/JP2001525356A/ja
Priority to DE69817602T priority patent/DE69817602T2/de
Priority to EP98962780A priority patent/EP1033972B1/en
Priority to DK98962780T priority patent/DK1033972T3/da
Publication of SE9704549L publication Critical patent/SE9704549L/sv
Publication of SE513149C2 publication Critical patent/SE513149C2/sv

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9704549A 1997-12-05 1997-12-05 Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna SE513149C2 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9704549A SE513149C2 (sv) 1997-12-05 1997-12-05 Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
DK98962780T DK1033972T3 (da) 1997-12-05 1998-12-04 Medikamenttilførselssystem med totrinsmålretning
AU17938/99A AU745059B2 (en) 1997-12-05 1998-12-04 Drug delivery system with two-step targeting
PCT/SE1998/002231 WO1999029302A1 (en) 1997-12-05 1998-12-04 Drug delivery system with two-step targeting
US09/555,329 US6562316B1 (en) 1997-12-05 1998-12-04 Drug delivery system with two-step targeting
CA002312767A CA2312767C (en) 1997-12-05 1998-12-04 Drug delivery system with two-step targeting
AT98962780T ATE247949T1 (de) 1997-12-05 1998-12-04 Arzneistoffverabreichungssystem mit zweistufigem targeting
JP2000523974A JP2001525356A (ja) 1997-12-05 1998-12-04 ２工程標的設定を用いた薬物送達システム
DE69817602T DE69817602T2 (de) 1997-12-05 1998-12-04 Arzneistoffverabreichungssystem mit zweistufigem targeting
EP98962780A EP1033972B1 (en) 1997-12-05 1998-12-04 Drug delivery system with two-step targeting

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704549A SE513149C2 (sv) 1997-12-05 1997-12-05 Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna

Publications (3)

Publication Number Publication Date
SE9704549D0 SE9704549D0 (sv) 1997-12-05
SE9704549L true SE9704549L (sv) 1999-06-06
SE513149C2 SE513149C2 (sv) 2000-07-17

Family

ID=20409286

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9704549A SE513149C2 (sv) 1997-12-05 1997-12-05 Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna

Country Status (10)

Country Link
US (1) US6562316B1 (sv)
EP (1) EP1033972B1 (sv)
JP (1) JP2001525356A (sv)
AT (1) ATE247949T1 (sv)
AU (1) AU745059B2 (sv)
CA (1) CA2312767C (sv)
DE (1) DE69817602T2 (sv)
DK (1) DK1033972T3 (sv)
SE (1) SE513149C2 (sv)
WO (1) WO1999029302A1 (sv)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0963758A3 (en) * 1998-05-07 2000-03-22 Universiteit Gent Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells
DE19905094C1 (de) * 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel
EP1880736A1 (en) * 1999-04-23 2008-01-23 Alza Corporation Releasable linkage and composition containing same
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
EP1926780B1 (en) 2005-09-22 2013-08-14 Medivas, LLC Bis-( -amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
US8835614B2 (en) 2008-12-16 2014-09-16 Genzyme Corporation Oligosaccharide-protein conjugates
EP2413906B1 (en) 2009-03-31 2017-03-15 The Board of Trustees of the University of Arkansas Method of controlled drug release from a liposome carrier
WO2012112317A1 (en) * 2011-02-15 2012-08-23 Albert Einstein College Of Medicine Of Yeshiva University Radiobacteria for therapy of cancer
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
EP2723800B1 (en) 2011-06-23 2015-10-07 DSM IP Assets B.V. Micro- or nanoparticles comprising a biodegradable polyesteramide copolymer for use in the delivery of bioactive agents
WO2013070872A1 (en) 2011-11-08 2013-05-16 The Board Of Trustees Of The University Of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
WO2016097297A1 (en) 2014-12-18 2016-06-23 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
US11492670B2 (en) 2015-10-27 2022-11-08 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
US20220273382A1 (en) 2019-08-01 2022-09-01 Indian Institute Of Science A method for locomotion of a nanorobot and implementations thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613937B1 (fr) * 1987-04-17 1989-07-21 Ire Celltarg Sa Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer
US5328678A (en) * 1987-11-04 1994-07-12 Vestar, Inc. Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
IE914220A1 (en) * 1990-12-10 1992-06-17 Akzo Nv Labelled, modified oligonucleotides
EP0626943B1 (en) * 1991-10-31 2000-01-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Bistriazenes as chemotherapeutic agents
US5750390A (en) * 1992-08-26 1998-05-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US5674977A (en) * 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US5648532A (en) * 1993-06-03 1997-07-15 The Regents Of The University Of California Compositions for boron neutron capture therapy and methods thereof
CA2178341A1 (en) * 1993-10-15 1995-04-20 Eva M. Rakowicz-Szulczynska Detection and treatment of breast and gynecological cancer
US6180766B1 (en) * 1993-12-02 2001-01-30 Raymond F. Schinazi Nucleosides and oligonucleotides containing boron clusters
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
WO1995024928A2 (en) * 1994-03-15 1995-09-21 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
US5630786A (en) * 1994-06-27 1997-05-20 Ionix Corporation Boron neutron capture enhancement of fast neutron therapy
US5756668A (en) * 1994-11-15 1998-05-26 The Johns Hopkins University School Of Medicine Hypermethylated in cancer polypeptide, HIC-1
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
JP2000509404A (ja) * 1996-05-08 2000-07-25 ニカ ヘルス プロダクツ リミテッド 遺伝物質の導入システムとしてのカチオン性ヴィロソーム
AU2911197A (en) * 1996-05-24 1998-01-05 Imperial College Of Science, Technology And Medicine Polycationic sterol derivatives as transfection agents

Also Published As

Publication number Publication date
US6562316B1 (en) 2003-05-13
JP2001525356A (ja) 2001-12-11
DE69817602D1 (de) 2003-10-02
SE513149C2 (sv) 2000-07-17
EP1033972A1 (en) 2000-09-13
CA2312767C (en) 2009-04-07
AU745059B2 (en) 2002-03-07
WO1999029302A1 (en) 1999-06-17
DK1033972T3 (da) 2003-12-22
AU1793899A (en) 1999-06-28
CA2312767A1 (en) 1999-06-17
EP1033972B1 (en) 2003-08-27
SE9704549D0 (sv) 1997-12-05
ATE247949T1 (de) 2003-09-15
DE69817602T2 (de) 2004-06-24

Similar Documents

Publication Publication Date Title
SE9704549D0 (sv) Drug delivery system
NZ336511A (en) Treating prostatic diseases using delayed and/or sustained release formulations of activated vitamin D
Neuwelt et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity
EP1455840A4 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR TNF-ALPHA
AU3354500A (en) Dramatic simplification of a method to treat neoplastic disease by radiation
BR0312664A (pt) Composição farmacêutica e uso da enzima urease para a fabricação de um medicamento para o tratamento de células cancerìgenas em um indivìduo
AU4338501A (en) Combination chemotherapy
AU2001236529A1 (en) Combination therapy for cancer
Dische Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanoma
Looney et al. Solid tumor models for the assessment of different treatment modalities. XXII. The alternate utilization of radiotherapy and chemotherapy
WO2005013802A3 (en) Trefoil factor 3 (tff3) as a target for anti-cancer therapy
Hopkins et al. The effect of varying the time between irradiation and cyclophosphamide on growth response of hepatoma 3924A
UA30257A (uk) Спосіб нормалізації тканинного обміну та відновлення морфофункціонального стану органів і тканин
Nutting et al. Radiation Therapy and Soft Tissue Response
RU2204427C1 (ru) Способ фотодинамической терапии злокачественных поражений плевры
DE69724228D1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
Rosen et al. Sequelae of radiation facial epilation (North American Hiroshima maiden syndrome
Meral et al. Role of vitamin E in decreasing the toxic effect of digoxin
RU94035764A (ru) Способ лечения онкологического заболевания
Struwig Microcurrent therapy
Serafini Systemic Metabolic Radioisotope Therapy in the Management of Bone Pain
Henderson Chemotherapy treatments: chemotherapy for breast cancer
Wang Head and neck: Treatment of primary and relapsed nasopharyngeal carcinoma
Stevenson et al. Beneficial liaisons: Radiobiology meets cellular and molecular biology
RU94021014A (ru) Способ лечения злокачественных опухолей методом фотодинамической терапии

Legal Events

Date Code Title Description
NUG Patent has lapsed